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Abstract: Once daily dosing of aminoglycosides has been introduced and validated in non-neonatal patient co-
horts. This is because aminoglycosides display peak concentration dependent bacterial killing, have a post-
antibiotic effect and adaptive resistance. In addition, this strategy reduces toxicity. Although aminoglycosides are 
also frequently administered to neonates, there is still debate about how to integrate and extrapolate these extended 
interval dosing regimens into dosing schedules tailored for neonates. There is a growing body of knowledge on 
aminoglycoside disposition and its covariates (e.g. asphyxia, ibuprofen or indomethacin exposure, serum creatin-
ine, sepsis, dose accuracy) in neonates. In essence, integration of developmental physiology with clinical pharmacology unveils a dis-
crepancy between aspects related to either body composition (higher distribution volume necessitates higher dose, to attain peak concen-
tration) or to elimination clearance (lower renal clearance necessitates prolonged time interval between administrations).  
Such discrepancy can be solved by introducing more complex dosing guidelines (based on weight, postnatal age, serum creatinine, ibu-
profen, asphyxia) in neonates. However, the introduction of more complex dosing guidelines should be balanced with its clinical feasibil-
ity. At least, there are reports that these more complex dosing guidelines result in a higher incidence of dosing errors. Besides errors in 
prescription, these errors also relate to the number of dilutions or manipulations needed before the prescribed dose can be administered. 
Since an integrated approach is needed, we discuss in this overview both the available pharmacokinetic data in support of the use of ex-
tended dosing regimens in neonates as well as the strategies suggested to reduce dosing errors.  
Keywords: Pharmacodynamics, pharmacokinetics, newborn, aminoglycosides, renal function, extended interval dosing, safety, care bundle. 
INTRODUCTION: AMINOGLYCOSIDES IN NEONATES  
 Antibiotics are the most frequently administered drugs in a 
neonatal intensive care unit (NICU) setting, with penicillines and 
aminoglycosides as most commonly administered classes of antibi-
otics. Usually, a combination of an aminoglycoside (e.g. gentami-
cin, amikacin, netilmicin, tobramycin, kanamycin) and a beta-
lactam antibiotic (e.g. penicillin G, ampicillin, amoxicillin, cepha-
losporins), are administered to treat suspected or proven bacterial 
infections in neonates. [1-4]. Aminoglycosides are traditionally 
administered for confirmed aerobic, Gram-negative infections (e.g. 
E. Coli, Enterobacter species, Klebsiella species, Pseudomonas 
species) or rather empirically for suspected congenital or nosoco-
mial bacterial infections. There is a synergism with beta-lactam 
antibiotics for group B streptococcal and coagulase-negative 
staphylococcal infections. The bactericidal efficacy for gram-
negative pathogens, the synergism with beta-lactam antibiotics, the 
limited bacterial resistance and bacterial selection pressure and the 
low cost contributed to this practice [5].  
 Despite their routine administration, most of these compounds 
are still administered in an off-label or unlicensed setting [6,7]. 
Similar to other pediatric and non-pediatric populations in whom 
these extended dosing interval have been validated, there is a shift 
towards ‘once daily’ or more accurate for neonates, ‘extended dos-
ing interval’ approaches. This is because the primary pharmacody-
namic outcome of aminoglycosides, i.e. bactericidal efficacy exclu-
sively relates to the pharmacokinetics of the aminoglycosides, irre  
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spective of the characteristics of the host [5,9-12]. However, the 
development and introduction of such dosing regimens needs some 
population specific tailoring.  
 The combination of in vitro and in vivo bactericidal characteris-
tics resulted in a classification of antibiotics according to their spe-
cific pharmacokinetic/pharmacodynamic (PK/PD) relationship 
[1,5]. When we focus on bacterial growth inhibition or killing, a 
variable concentration-response depending on this classification 
needs to be considered. Minimal Inhibitory Concentration (MIC) 
values and the most effective strategy to aim for relate to both the 
antibiotic and the pathogen. For instance, maintaining the serum 
concentration > 4 times the MIC is the goal for beta-lactams, while 
reaching a peak/MIC ratio > 8 is applied for aminoglycosides [5]. 
Because of differences in susceptibility of gram negative bacteria to 
gentamicin, tobramycin and netilmicin compared to amikacin, the 
equivalent concentration of amikacin is 3-4 times higher, necessitat-
ing 3-4 times higher amikacin concentrations [5].  
 The peak/MIC ratio relevance for aminoglycosides is because 
these compounds display concentration-dependent bacterial killing. 
Aminoglycoside mediated bacterial killing results from inhibition 
of bacterial protein synthesis through irreversible binding to the 30S 
bacterial ribosome and results in deficient bacterial protein produc-
tion. This uptake necessitates an active uptake process [5]. There 
are however additional observations that suggest that the outer bac-
terial membrane itself is also an important direct target for bacterial 
killing. Aminoglycosides induce fissures in the outer bacterial cell 
membrane, resulting in leakage of intracellular contents and hereby 
enhance subsequent (passive) antibiotic diffusion. This may in part 
also explain the earlier mentioned synergism with beta-lactam anti-
biotics, since beta-lactam antibiotics act by inhibiting the synthesis 
of the peptidoglycan layer of bacterial cell wall [1,8]. 
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 Based on in vitro and on extrapolation of in vivo observations in 
non-neonatal populations, it is generally accepted to aim for a peak 
aminoglycoside concentration (Cpeak) to minimal inhibitory concen-
tration (MIC) ratio (Cpeak/MIC) of at least 8. Besides concentration 
dependent killing, there are some other issues to consider when we 
aim to further improve the PK/PD relation of aminoglycosides in 
neonates. We would like to mention the post-antibiotic effect, the 
concept of adaptive resistance, and the aminoglycoside exposure 
related toxicity (ototoxicity, nephrotoxity).  
 The post-antibiotic effect refers to the observation that the bac-
terial growth remains suppressed for at least several hours after the 
serum concentration of a given aminoglycoside has dropped below 
the pathogen specific MIC value [1,5,8]. Adaptive resistance refers 
to the observation that there is a reduction in antimicrobial killing 
of initially susceptible bacteria during ongoing aminoglycoside 
exposure. This very likely relates to bacterial membrane protein 
changes and altered expression of regulatory genes of the anaerobic 
respiratory pathway, and can be overcome with higher peak con-
centrations [1,5,8]. Very recently, a pharmacokinetic-pharmaco-
dynamic model for gentamicin and its adaptive resistance with pre-
dictions of dosing schedules in newborn infants has been reported. 
The model supported an extended dosing interval of gentamicin in 
preterm neonates, and for all neonates, dosing intervals of 36 to 48 
h were as effective as a 24-h dosing interval for the same total dose. 
However, prospective validation of such model efforts are urgently 
needed [11].  
 Besides the above mentioned issues (peak concentration, post-
antibiotic effect, adaptive resistance) related to more effective (i.e. 
bactericidal) administration of aminoglycosides, there are also ob-
servations in support of the association of extended dosing intervals 
and reduced aminoglycoside toxicity [5,8]. In contrast to the phar-
macokinetics, the pharmacodynamics and toxicity of aminoglyco-
sides are only in part unrelated to the population evaluated (e.g. 
bacterial resistance), since other aspects (inhibition of neuromuscu-
lar synaptic activity, nephrotoxicity, oto and vestibulo-toxicity, 
colonizing intestinal microbiota) may either by difficult to diagnose 
(neuromuscular synaptic activity, vestibulo-toxicity) in neonates or 
may have age-specific relevance (e.g. colonizing intestinal microbi-
ota) [13]. Moreover, cohort studies describe associations that not 
necessary reflect causal relations between aminoglycoside exposure 
and oto- or nephrotoxicity [14]. 
 There are two different patterns for aminoglycoside-induced 
ototoxicity. Ototoxicity may either result due to sustained high 
trough levels or is genetically determined. Several mitochondrial 
DNA variants in the 12S rRNA gene (MT-RNR1) are associated 
with aminoglycoside induced hearing loss [15]. The higher toxicity 
is due to more effective uptake with subsequent accumulation in the 
inner ear hair cells with subsequent cell death merely since these 
mitochondrial variants are structurally more similar to the bacterial 
ribosomal RNA. Permanent bilateral hearing loss occurs in 0.1 to 
0.3 % of all live births with an increased risk in NICU graduates (1-
4 %), depending on the clinical characteristics of the population 
reported. Neonatal hearing screening is based on auditory brain 
stem response (ABR), oto-acoustic emissions (OAE), or both [16-
21].  
 To illustrate the difficulty to explore the impact of ototoxic 
medications on hearing impairment, we refer to the cohorts evalu-
ated by ABR reported following exposure to tobramycin (n=625) or 
amikacin (n=615) [16,17]. de Hoog et al. observed failed ABR 
screening in 45/625 (7.2 %) while our group observed failed ABR 
screening in 70/615 (11 %) and confirmed hearing impairment in 
25/615 (4 %). However, no independent association with aminogly-
coside exposure (levels, duration) could be documented in both 
cohorts [16,17]. In the Leuven cohort, syndromal/congenital mal-
formations (10/25) and cytomegalovirus infection (4/25) were the 
most relevant risk factors [17].  
 Cooper et al. reported on OAE screen results in 528 critically ill 
neonates, including both very low birth weight infants (VLBW, 
<1500g) as well as more mature neonates [18]. The overall inci-
dence of OAE screening failure was 69/528 (13.1 %) and was 
higher in the VLBW cohort (29/85, 34 %), but there was only a 
significant association between screening failure and gentamicin 
exposure in the more mature group [18]. Using the same OAE as-
sessment in 2 347 neonates, Vella-Brincat et al. were unable to 
provide evidence of an increased risk of ototoxicity following neo-
natal gentamicin exposure, but described an association with van-
comycin exposure [19]. Finally, using both OAE and ABR, there 
were no significant differences in hearing impairment when a 24 h 
gentamicin dosing regimen was compared to a 48 h regimen in 
extreme preterm neonates (< 28 weeks) [20]. In the meta-analysis 
on the effectiveness and safety of extended interval dosing in neo-
nates of Nestaas et al., data on hearing assessment were available in 
210 neonates, with only one neonate with hearing impairment [21]. 
However, we would like to mention that there is still an need for 
data on long term hearing outcome or on vestibulotoxicity.  
 The pathogenesis of renal impairment relates to intracellular 
lysosomal accumulation of the aminoglycoside in the proximal 
renal tubular cells after glomerular filtration [22]. This accumula-
tion leads to renal tubular cell damage and leakage of specific en-
zymes (e.g. retinol binding protein, N-acetyl-beta-D-glucosamini-
dase, alkaline phosphatase, alanine aminopeptidase, gamma-
glutamyltransferase, alpha-1 microglobulin) or phospholipids in the 
urine [22]. This is an active but saturable transport, explaining why 
the median or trough instead of peak aminoglycoside level are bet-
ter predictors of nephrotoxicity. Focused studies on the renal side 
effects of extended interval dosing of amikacin, netilmicin or gen-
tamicin were unable to document any protective effect of extended 
interval dosing [20,23,24]. Similarly, in the meta-analysis on the 
effectiveness and safety of extended interval dosing in neonates of 
Nestaas et al., data on renal outcome were available in 589 neonates 
[21]. Depending on the renal biomarker used, the association of 
renal dysfunction and aminoglycoside exposure was common 
(raised serum creatinine = 30/40 patients, alanine amino-peptides = 
20/20) in both groups without significant differences between ‘tra-
ditional dosing, <24 h’ and ‘extended interval dosing, > 24 h’ [21].  
 To put these renal side effects into the broader neonatal inten-
sive care setting, we would like to mention that neither Cataldi et 
al. nor Vieux et al. were able to document in 172 (serum creatinine) 
and 269 (creatinine clearance) preterm neonates respectively that 
aminoglycosides had an independent significant negative effect on 
renal function [25-27]. However, transient renal tubular dysfunction 
after aminoglycosides has been described, and may warrant moni-
toring of electrolytes in specific cases [28]. Finally, because of the 
specific developmental characteristics in preterm neonates, with 
glomerulogenesis as an extra-uterine event up to 34 weeks of post-
menstrual age, nephrotoxic drugs taken during fetal life and during 
postnatal nephrogenesis could interfere with nephron generation 
contributing to a particular magnitude of damage [29]. Such adjunc-
tive damage could further increase the risk of renal failure in the 
adulthood of children born prematurely. At least, there is an need to 
further document long term renal outcome in former preterm neo-
nates [29,30].  
 In conclusion, the concepts of post antibiotic effect, adaptive 
resistance and the pathogenesis of aminoglycoside-induced toxicity 
provide evidence in support of the extended interval dosing, applied 
to further improve the PK/PD relation of aminoglycosides. How-
ever, convincing evidence on improved efficacy or reduced toxicity 
in neonates is still lacking. A higher dose results in a higher 
Cpeak/MIC ratio, adaptive resistance can be avoided due to higher 
Cpeak, the post antibiotic effect facilitates to further extend the time 
interval between administrations while the time interval mainly 
relates to prevent aminoglycoside-induced toxicity and reduction of 
the median concentration.  
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 The major challenge in neonates is however to maximize these 
concepts to result in a more efficacious treatment in the context of 
their immature distribution and excretion pathways, while still us-
ing dosing guidelines and precautions to avoid dosing errors: the 
balance between physiology and feasibility [31-33].  
COVARIATES OF AMINOGLYCOSIDE PHARMACOKI-
NETICS IN NEONATES 
 Drug dosing in neonates should be based on knowledge con-
cerning the physiological characteristics of the newborn that will 
receive the drug, and the pharmacokinetic and –dynamic parameters 
of a given compound [33-35]. This means that for antibiotics, popu-
lation specific estimates on pharmacokinetics and its covariates are 
of utmost importance to propose effective dosing regimens. It is 
reasonable to assume that all aminoglycosides display a similar 
disposition pattern and reflect the ontogeny of glomerular filtration 
rate [36,37]. For both pharmacokinetic estimates (distribution vol-
ume, clearance), we have similar maturational patterns, irrespective 
of the specific aminoglycoside considered, making extrapolation 
beyond compound specific observations feasible and relevant 
[37,38]. The most relevant contributors of aminoglycoside PK in 
neonates consequently are age, weight, and renal elimination capac-
ity (glomerular filtration rate).  
 Aminoglycosides are water soluble and are unbound to plasma 
proteins. Consequently, the distribution volume (Vd) reflects the 
water content of the body and its covariates in neonates. Aminogly-
cosides are primary eliminated by glomerular filtration and conse-
quently, reflect glomerular filtration rate and its covariates in neo-
nates [34-38]. The main driver of changes in distribution volume is 
the age related, maturational decrease in the proportions of extracel-
lular body water content. Within the neonatal population, there are 
reports on the impact of a symptomatic patent ductus arteriosus, 
sepsis or the use of extracorporeal membrane oxygenation (ECMO) 
on this body water content [39-41]. All these covariates increase the 
distribution volume (l/kg) and consequently, result in a proportional 
decrease of the peak aminoglycoside concentration if dosing 
(mg/kg) remains unaltered.  
 The main drivers of changes in glomerular filtration rate in 
neonates are (birth)weight and age (postnatal age, postmenstrual 
age, gestational age). As recently described by Vieux et al. in a 
cohort of 269 preterm neonates, creatinine clearance relates to both 
gestational age and postnatal age with already a 5-fold range (7.9-
37.9 ml/min.1.73m
2
) despite the limited age (27-31 weeks at birth) 
range at inclusion [26,27]. When extreme preterm (<27 weeks) or 
(near)term neonates are also considered, this range increases to > 10 
fold difference in aminoglycoside clearance within neonatal co-
horts.  
 In addition to these maturational changes, disease characteris-
tics and co-medication may further affect aminoglycoside clear-
ance. Besides gestational and postnatal age, exposure to ibuprofen 
explained in part the variability in creatinine clearance observed by 
Vieux et al [27]. Similarly, co-administration of either ibuprofen or 
indomethacin results in a clinical relevant reduction in aminoglyco-
side clearance [42,43]. In Figure 1, we illustrate the impact of ibu-
profen exposure on amikacin elimination half life (h) in a cohort of 
preterm neonates at birth [44]. Since these patients were included in 
a randomized, double blinded, controlled trial to document the im-
pact of ibuprofen prophylaxis, the differences in amikacin clearance 
do reflect the impact of ibuprofen exposure [44,45].  
 This phenomenon is not limited to ibuprofen, but has also been 
quantified for other non-steroidal anti-inflammatory drugs, includ-
ing indomethacin [43]. Administration of indomethacin or ibupro-
fen in neonates is associated with a reduction of the glomerular 
filtration rate, reflected in a reduction in the elimination of drugs 
dependent on renal function for clearance. The impact of indo-
methacin co-administration on renal aminoglycoside clearance  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Amikacin elimination serum half life (h) at birth in extreme pre-
term neonates with or without exposure to prophylactic ibuprofen admini-
stration, started in the first 6 h of postnatal life [44]. 
 
might explain the differences in trough levels observed by 
Thingvoll et al. versus Rastogi et al., both evaluating an extended 
interval dosing in very preterm neonates [20,46]. The incidence of 
gentamicin trough levels < 0.5 g/ml in a 48 h dosing group was 30 
% in the Rastogi cohort while absent in the Thingvoll cohort. Be-
sides differences in median birth weight (1 040 vs 743 g), the 
Thingvoll cohort was co-treated with indomethacin as part of pro-
phylaxis to prevent intraventricular hemorrhage [20,46]. Similar 
observations have been reported for netilmicin. Based on 46 treat-
ment courses, 11 trough netilmicin levels were above the trough 
level aimed for (< 4 mol/l), of whom 7 were in their first week of 
life, and 5/7 co-treated with indomethacin [47]. Finally, Langhen-
dries et al. suggested a dose extension for amikacin of 6h when co-
exposed to indomethacin, but did not explicitly quantified the im-
pact of indomethacin on the amikacin clearance [23]. Peripartal 
asphyxia is another subgroup of neonates that warrants focused 
attention since renal failure is commonly associated with this condi-
tion [48]. In essence, aminoglycoside clearance is reduced in these 
neonates but this clearance is not further affected by therapeutic 
hypothermia [49]. Finally, reduced clearance has also been de-
scribed during ECMO [41].  
 In the absence of ibuprofen or indomethacin exposure, peripar-
tal asphyxia or ECMO, it seems reasonable to predict aminoglyco-
side clearance based on weight and/or age (postmenstrual age, ges-
tational age, postnatal age) [3,4,50]. De Cock et al. recently illus-
trated this based on population pharmacokinetic modelling using 
amikacin therapeutic drug monitoring data from 874 neonates (ges-
tational age 24-43 weeks; postnatal age 1-30 days; birth weight 
385-4650 g). The influence of different age-related, weight-related 
and other covariates was investigated. Postmenstrual age was the 
most significant covariate on clearance. However, the combination 
of birth weight and postnatal age proved to be superior to postmen-
strual age alone, while co-administration of ibuprofen proved to be 
a third covariate [37]. In contrast, serum creatinine was not an inde-
pendent covariate in this model. This is because serum creatinine 
values in neonates do not yet fully reflect the neonatal glomerular 
filtration rate [51-55]. Creatinaemia at birth does not yet reflect 
neonatal but maternal creatinine clearance and because of passive 
tubular back leak instead of active secretion, creatinine clearance 
does not yet fully reflects GFR [51-55]. Finally, absolute serum 
creatinine values also depend on the analytic technique used [55].  
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Fig. (2). Postnatal median trends of serum creatinine in neonates of various 
birth weight categories.  
All data presented by mg/dl, all serum creatinine values were determined 
based on enzymatic quantification [< 1 kg (‡), 1-2 kg, (+), 2-3 kg (

) and >3 
kg ()]. Peak values are higher and later in the most immature cases, with a 
subsequent slower decrease in these neonates.  
[X-axis = postnatal age, days; Y-axis = serum creatinine, mg/dl]. 
 
In the absence of strong arguments in support of universal therapeu-
tic drug monitoring (TDM) for aminoglycosides, it seems also rea-
sonable to limit TDM to specific settings (e.g. peripartal asphyxia, 
ECMO) or prolonged administration [3,4,50].  
FROM DEVELOPMENTAL PHYSIOLOGY TO BEDSIDE 
FEASIBILITY 
 The integration of maturational aspects of body composition 
(higher distribution volume necessitates higher dose to attain peak 
concentration) and maturational elimination clearance (lower renal 
clearance necessitates longer time interval between administrations) 
results in more complex dosing guidelines for aminoglycosides in 
neonates [4,10,11,12]. However, this conceptual superiority should 
be balanced with the introduction of more complex dosing guide-
lines in our clinics: its feasibility needs further considerations [56-
62]. Studies on the feasibility and safety to implement more com-
plex dosing guidelines are limited although there are some data on 
the problem of correct prescription of aminoglycosides. This feasi-
bility includes the (in)accuracy of dosing related to multiple drug 
manipulations or dilutions needed before a given compound can be 
administered [57]. We would like to provide some illustrations on 
the impact of formulations used (amikacin pediatric vial) [58], the 
effect of product availability (netilmicin withdrawal, New Zealand) 
[59] and on the gentamicin guidelines (UK) [56,60,61]. Although 
all cases relate to aminoglycosides, these cases also serve as illus-
trations of the multifactorial origin of medication errors and the 
need of a multifactorial approach to promote safe medication prac-
tices.  
 Based on consecutive reports on interindividual amikacin clear-
ance in extreme preterm (< 31 weeks gestational age) neonates at 
birth, we confirmed the impact of age and ibuprofen on amikacin 
clearance [42,44,58]. However, there was still unexplained variabil-
ity with a clinical relevant portion of trough amikacin levels (37 %) 
above the desired trough level. We assumed that this unexplained 
variability in amikacin clearance was at least in part caused by un-
intended variability in dosing accuracy, inherent to any manipula-
tion of drugs and anticipated that formulations adapted for use in 
neonates would result in a more accurate administration of the in-
tended dose. The administration of low volumes or the need for 
sequential dilutions may cause additional systematic errors. Follow-
ing the introduction of a pediatric vial (50 mg/ml instead of 250 
mg/ml), a further reduction of the interindividual variability of ami-
kacin clearance with a reduction in the number of plasma concen-
trations above the desired trough level (73 %) was documented 
[58]. Based on a more complex population pharmacokinetic model, 
we confirmed that the switch form an ‘adult’ to ‘pediatric’ vial 
resulted in a reduction of observed variability in both distribution 
volume and clearance [58]. This is a strong argument in support of 
improved dosing accuracy following this switch. We like to present 
the following clinical example to further illustrate this. The dose of 
amikacin is 15 to 20 mg/kg in neonates. Based on the mean weight 
(1078 g) of the cohort evaluated, this means that 21.5 mg of ami-
kacin, equivalent to 0.085 ml of the adult vial or 0.43 ml of the 
pediatric vial should be administered. Obviously, the use of the 
highly concentrated vial and very low volume results in more dos-
ing inaccuracy. This observation hereby supports the relevance of 
neonatal ‘tailored’ vials, and this clinical relevance is obviously not 
limited to aminoglycosides, but also includes e.g. opioids, sedatives 
or anti-epileptics [57]. This dosing inaccuracy is not limited to the 
preparation itself, since Sherwin et al. documented that the discrep-
ancies between predicted and observed gentamicin exposure in an 
ex vivo model increased with smaller volumes and lower infusion 
rate [62]. We refer the interested reader to a recently published 
research protocol of a systematic review on the manipulation of 
drugs to obtain the required dose [27].  
 Besides adapted vials, unavailability or product withdrawal may 
affect routine practices, but potentially also efficacy and perform-
ance. Sherwin et al. reported on the impact of netilmicin with-
drawal from marketing in New Zealand in 2003 [59]. The authors 
hereby provide evidence that the switch from netilmicin (1999-
2003) to amikacin (2003-2007) was associated with an increase in 
treatment failures in the Dunedin NICU. There were differences in 
dosing regimen applied, in pathogens isolated and the design of the 
study was only observational. However, this association at least 
suggest that the withdrawal of a compound of which caregivers had 
extensive prior experience to a compound new to their practice may 
negative effects upon their clinical care. 
 Drug prescription errors are common, multifactorial and multi-
professional. Consequently, the use of a care bundle is considered 
to be an appropriated, structured approach for improvement of a 
care process. A bundle consists of a limited number of specific 
practices, when implemented together, result in improvement of 
patient outcome. Such a care bundle has been developed to improve 
gentamicin administration in the UK following the observation that 
15 % of the medication related errors related to gentamicin admini-
stration, included incorrect time, prescribing error or therapeutic 
drug monitoring related issues [56]. Based on these observations, 
the gentamicin care bundle focusses on incorrect time (the recom-
mendation to use the 24-hour clock format) and on the need for a 
prompt double-check during preparation and administration without 
interruptions. Finally, the prescribed dose should be given within a 
time phrame of one hour before or after the prescribed time. In 
combination with a local neonatal gentamicin protocol, the assess-
ment of compliance to this care bundle and training of the staff 
involved in the prescription and administration, the National Patient 
Safety Agency aims to reduce these medication related errors [56].  
 Since this Patient Safety Alert publication, there are at least two 
interesting observations reported that may have not been considered 
sufficiently, i.e. how should a dosing chart be presented, and sec-
ondly, how consistent are gentamicin dosing protocols between 
different units. Wong et al. recently evaluated the impact of a sim-
plified dosing chart for gentamicin compared to the BNFc reference 
[60]. Errors related to the selection of the incorrect regimen, wrong 
frequency and one 10-fold dosing error. The pivotal difference 
between both charts related to the fact that in the revised version, 
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the concept of postconceptional age was further elaborated to gesta-
tional + postnatal age (in weeks). It seemed that some careproviders 
misinterpreted ‘postconceptional age’, while this was no longer the 
case when ‘gestational + postnatal age’ was applied. At least, the 
paper re-informs us on the need to check dosing charts on the uni-
form interpretation.  
 The lack of consistence between different units has been de-
scribed by Kadambari et al [61]. Based on a questionnaire analysis 
with answers of 43 different units, 10 different gentamicin dosing 
regimens were used, depending on gestational age and/or weight. 
Since both medical and nursing staff may rotate through different 
hospitals, this may result in yet another risk factor for dosing errors.  
 These comments bring us back to the main message of this 
paper. There is still debate about how to integrate and extrapolate 
the extended interval regimens of aminoglycosides into dosing 
schedules tailored for neonates. These extended interval regimens 
are the final result of the discrepancy between aspects related to 
either body composition (higher distribution volume necessitates 
higher dose to attain peak concentration) or to elimination clear-
ance (lower renal clearance necessitates longer time interval be-
tween administrations). Such discrepancy can only be solved by 
introducing more complex dosing guidelines. However, the intro-
duction of more complex dosing guidelines should be balanced with 
the clinical feasibility. Consequently, the introduction of extended 
dosing regimens should be supported by strategies to reduce or 
avoid dosing errors.  
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